105 related articles for article (PubMed ID: 21239021)
1. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
Shteynshlyuger A; Andriole GL
J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
[TBL] [Abstract][Full Text] [Related]
2. Reconsidering the Trade-offs of Prostate Cancer Screening.
Shoag JE; Nyame YA; Gulati R; Etzioni R; Hu JC
N Engl J Med; 2020 Jun; 382(25):2465-2468. PubMed ID: 32558473
[No Abstract] [Full Text] [Related]
3. The ERSPC Study: Quality Takes Time and Perseverance.
Roobol MJ; Carlsson SV
Clin Chem; 2019 Jan; 65(1):208-209. PubMed ID: 30459163
[No Abstract] [Full Text] [Related]
4. Prostate cancer screening algorithms and the Affordable Care Act updates.
Gomella LG
Can J Urol; 2023 Oct; 30(5):11644. PubMed ID: 37838989
[No Abstract] [Full Text] [Related]
5. Prostate cancer screening: Unacceptable in the under 50s.
Braillon A; Dubois G
BMJ; 2007 Dec; 335(7632):1225. PubMed ID: 18079521
[No Abstract] [Full Text] [Related]
6. Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
Van Poppel H; Roobol MJ; Chandran A
Eur Urol; 2023 Dec; 84(6):519-522. PubMed ID: 37704541
[TBL] [Abstract][Full Text] [Related]
7. Eight Misconceptions about Prostate-Specific Antigen.
Vickers AJ; Lilja H
Clin Chem; 2024 Jan; 70(1):13-16. PubMed ID: 38175588
[No Abstract] [Full Text] [Related]
8. What is the true mortality benefit of prostate-specific antigen screening?
Loeb S; Partin AW
Rev Urol; 2010; 12(1):66-7. PubMed ID: 20428297
[No Abstract] [Full Text] [Related]
9. Advice About Screening for Prostate Cancer With Prostate-Specific Antigen.
Jean-Pierre G
J Adv Pract Oncol; 2017; 8(6):639-645. PubMed ID: 30310725
[No Abstract] [Full Text] [Related]
10. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
12. A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.
Garg V; Gu NY; Borrego ME; Raisch DW
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):327-42. PubMed ID: 23763530
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men.
Gustafsson O; Carlsson P; Norming U; Nyman CR; Svensson H
Prostate; 1995 Jun; 26(6):299-309. PubMed ID: 7540297
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of CDCA8 Predicts Poor Prognosis and Promotes Tumor Cell Growth in Prostate Cancer.
Wan S; He Y; Zhang B; Yang Z; Du FM; Zhang CP; Fu YQ; Mi J
Front Oncol; 2022; 12():784183. PubMed ID: 35449575
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological and Economic Evaluation of a Pilot Prostate Cancer Screening Program.
Smailova DS; Fabbro E; Ibrayev SE; Brusati L; Semenova YM; Samarova US; Rakhimzhanova FS; Zhussupov SM; Khismetova ZA; Hosseini H
Prostate Cancer; 2020; 2020():6140623. PubMed ID: 32411478
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
18. High-Throughput, Time-Resolved Mechanical Phenotyping of Prostate Cancer Cells.
Belotti Y; Tolomeo S; Conneely MJ; Huang T; McKenna SJ; Nabi G; McGloin D
Sci Rep; 2019 Apr; 9(1):5742. PubMed ID: 30952895
[TBL] [Abstract][Full Text] [Related]
19. Changes in Clinical Characteristics of Patients with an Initial Diagnosis of Prostate Cancer in Korea: 10-Year Trends Reported by a Tertiary Center.
Heo JE; Ahn HK; Kim J; Chung BH; Lee KS
J Korean Med Sci; 2018 Feb; 33(6):e42. PubMed ID: 29349937
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
